申请人:National University Corporation Nagoya University
公开号:EP2749285A1
公开(公告)日:2014-07-02
The purpose of the present invention is to provide an osteogenesis promoter that can be administered locally and systemically and that is suitable for clinical application. Provided is an osteogenesis promoter that contains, as an active ingredient, at least one compound selected from the group consisting of phenazopyridine hydrochloride, riluzole hydrochloride, tranilast, rabeprazole, indoprofen, nabumetone, luteolin, leflunomide, lansoprazole, methiazole, thiabendazole, albendazole, tiaprofenic acid, balsalazide sodium salt, and cyclosporin A, or a pharmaceutically acceptable salt thereof. Preferably, rabeprazole or lansoprazole, which are proton pump inhibitors, is used as an active ingredient.
本发明的目的是提供一种可局部和全身给药并适合临床应用的成骨
促进剂。本发明提供了一种成骨
促进剂,它含有至少一种选自由
盐酸苯并
吡啶、
盐酸利鲁唑、
氨非司特、
雷贝拉唑组成的组的化合物作为活性成分、
吲哚布洛芬、
萘丁美酮、
叶黄素、
来氟米特、
兰索拉唑、甲
噻唑、噻苯达唑、
阿苯达唑、噻丙芬酸、巴柳氮钠盐和
环孢素 A 或其药学上可接受的盐。最好使用
雷贝拉唑或
兰索拉唑(质子泵
抑制剂)作为活性成分。